T-Cell Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight's, "T-Cell Lymphoma Pipeline Insight" report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in T-Cell Lymphoma pipeline landscape. It covers the T-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the T-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive T-Cell Lymphoma Pipeline Report to explore emerging therapies, key T-Cell Lymphoma Companies, and future T-Cell Lymphoma treatment landscapes @ T-Cell Lymphoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the T-Cell Lymphoma Pipeline Report

* In February 2025;- Seagen Inc.:- This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side effects occur when brentuximab vedotin and CHP are used together. A side effect is anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat certain types of PTCL.
* In February 2025:- Janssen Scientific Affairs, LLC :- This study is designed to collect tissue samples from the biopsy specimen that was used to diagnose hepatosplenic T-cell lymphoma (HSTCL), additional patient information, and if possible, to obtain additional samples including a single blood sample, a buccal swab sample and/or a bowel tissue sample.
* In February 2025:- Daiichi Sankyo Co.:- This Phase 2 study will be conducted to assess the efficacy and safety of valemetostat tosylate (DS-3201b) in participants with relapsed or refractory adult T-cell leukemia/lymphoma (r/r ATL).
* In February 2025:- CRISPR Therapeutics:- The study may enroll up to 290 subjects in total. CTX131 is a CD70-directed chimeric antigen receptor (CAR) T cell immunotherapy comprised of allogeneic T cells prepared for the treatment of relapsed/refractory hematological malignancies. The cells are from healthy adult volunteer donors that are genetically modified ex vivo using CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats/ CRISPR-associated protein 9) gene editing components (single guide RNA and Cas9 nuclease).
* DelveInsight's T-Cell Lymphoma pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for T-Cell Lymphoma treatment.
* The leading T-Cell Lymphoma Companies such as Soligenix, CStone Pharmaceuticals, Genor Biopharma, Innate Pharma, ImmuneOncia Therapeutics, Astex Pharmaceuticals, Corvus Pharmaceuticals, ViGenCell Inc., Affimed GmbH, MediSix Therapeutics, Dialectic Therapeutics, Artiva Biotherapeutics, Inc ., and others.
* Promising T-Cell Lymphoma Therapies such as Alemtuzumab (Campath-1H), Duvelisib, Brentuximab vedotin, Pembrolizumab, Mogamulizumab, Enasidenib and others.

Discover how the T-Cell Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth T-Cell Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ T-Cell Lymphoma Clinical Trials and Studies [https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

T-Cell Lymphoma Emerging Drugs Profile

* SGX 301: Soligenix

SGX301 (HyBryte Trademark / synthetic hypericin) is a novel, first-in-class photodynamic therapy utilizing safe visible light for activation. SGX301 is a photodynamic topical therapy using a hypericin ointment activated by visible light which is intended for patients managing early stage CTCL disease progression. HyBryte Trademark has been granted both Orphan Drug and Fast Track designation in the US, Orphan Drug designation in Europe and Promising Innovative Medicine designation by the UK Health Authority. The company has submitted a new drug application (NDA) to the US FDA)for HyBryte Trademark (synthetic hypericin) in the treatment of early stage cutaneous T-cell lymphoma (CTCL).

* Sugemalimab: CStone Pharmaceuticals

Sugemalimab is an investigational anti-PD-L1 monoclonal antibody discovered by CStone. As a fully human, full-length anti-PD-L1 monoclonal antibody, sugemalimab mirrors the natural G-type immunoglobulin 4 (IgG4) human antibody, which reduces the risk of immunogenicity and potential toxicities in patients, a unique advantage over similar drugs. In September 2022, the National Medical Products Administration (NMPA) of China has accepted and granted priority review to the supplemental new drug application (sNDA) for sugemalimab in the treatment of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL).

* IMC-001: ImmuneOncia Therapeutics

IMC-001 (STI-3031) is a fully human anti-PD-L1 IgG1 type monoclonal antibody that has shown promising results in terms of safety and efficacy in the dose-escalation first-in-human study although the patients were heavily pretreated. IgG1 type antibody targeting PD-L1 on tumor enables unique combinations, such as with an NK cell-based therapy, unique in its property among other PD-1/PD-L1 targeting agents. The drug is in Phase II for the treatment of NK/T-cell lymphoma.

* Tolinapant: Astex Pharmaceuticals

Tolinapant (ASTX660) is a potent, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Tolinapant has a unique IAP antagonist molecular profile and has been shown to exert its activity through both IAP antagonism and via an immune-related mechanism. Currently, the drug is being evaluated in the Phase I/II (NCT05403450) for patients with peripheral T-cell lymphoma.

* CPI-818: Corvus Pharmaceuticals

CPI-818 is an oral, small molecular drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase) and has the potential to provide a platform opportunity with broad applicability across lymphomas, solid tumors and autoimmune/allergic diseases. The optimal dose of CPI-818 has the potential to induce the activation, differentiation and expansion of T cells to TH1 helper cells while blocking the deployment of TH2 cells (TH1 skewing). Corvus and its partner in China, Angel Pharmaceuticals are conducting a Phase I trial in patients with refractory T-cell lymphomas that was designed to select the optimal dose of CPI-818 and evaluate its safety, pharmacokinetics, target occupancy, immunologic effects, biomarkers and efficacy.

The T-Cell Lymphoma pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of T-Cell Lymphoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for T-Cell Lymphoma Treatment.
* T-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* T-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the T-Cell Lymphoma market.

Get a detailed analysis of the latest innovations in the T-Cell Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ T-Cell Lymphoma Unmet Needs [https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

T-Cell Lymphoma Companies

Soligenix, CStone Pharmaceuticals, Genor Biopharma, Innate Pharma, ImmuneOncia Therapeutics, Astex Pharmaceuticals, Corvus Pharmaceuticals, ViGenCell Inc., Affimed GmbH, MediSix Therapeutics, Dialectic Therapeutics, Artiva Biotherapeutics, Inc., and others.

T-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

T-Cell Lymphoma Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Download DelveInsight's latest report to gain strategic insights into upcoming T-Cell Lymphoma Therapies and key T-Cell Lymphoma Developments @ T-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the T-Cell Lymphoma Pipeline Report

* Coverage- Global
* T-Cell Lymphoma Companies- Soligenix, CStone Pharmaceuticals, Genor Biopharma, Innate Pharma, ImmuneOncia Therapeutics, Astex Pharmaceuticals, Corvus Pharmaceuticals, ViGenCell Inc., Affimed GmbH, MediSix Therapeutics, Dialectic Therapeutics, Artiva Biotherapeutics, Inc ., and others.
* T-Cell Lymphoma Therapies- Alemtuzumab (Campath-1H), Duvelisib, Brentuximab vedotin, Pembrolizumab, Mogamulizumab, Enasidenib and others.
* T-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* T-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in T-Cell Lymphoma drug development? Find out in DelveInsight's exclusive T-Cell Lymphoma Pipeline Report-access it now! @ T-Cell Lymphoma Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* T-cell Lymphoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* T-cell Lymphoma - DelveInsight's Analytical Perspective
* Late Stage Products (Pre-registration)
* SGX 301: Soligenix
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* IMC-001: ImmuneOncia Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* Tolinapant: Astex Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* T-cell Lymphoma Key Companies
* T-cell Lymphoma Key Products
* T-cell Lymphoma Unmet Needs
* T-cell Lymphoma Market Drivers and Barriers
* T-cell Lymphoma Future Perspectives and Conclusion
* T-cell Lymphoma Analyst Views
* T-cell Lymphoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=tcell-lymphoma-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/wolman-disease-market

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.